Lesson
Separate Colonization From Disease
Candida commonly inhabits mucosa. Disease begins when local ecology, tissue injury, immune control, organism behavior, and symptoms align.
- Colonization
- Mucosal barrier
- Cell-mediated immunity
- Compartment
ecology syndrome
Move from commensal ecology to disease only when the tissue compartment and host response support it.
Start with ecology
Candida can be present without causing illness. A culture or molecular signal from the mouth does not establish a treatment indication without compatible lesions or symptoms.
Identify disrupted control
Advanced HIV, corticosteroids, antibiotics, diabetes, malignancy therapy, dentures, xerostomia, malnutrition, and mucosal injury can shift commensal organisms toward disease.
Separate compartments
Oropharyngeal and esophageal candidiasis are mucosal syndromes, not candidemia. Esophageal disease is deeper than oral disease and always requires systemic treatment.
Look for invasive danger
Fever, hemodynamic instability, bloodstream risk, central lines, neutropenia, organ lesions, or persistent sepsis requires a separate invasive-candidiasis pathway.
Quick check
Lesson
Read the Oral Pattern and Its Drivers
Oropharyngeal disease is usually visible, but its forms overlap with nonfungal lesions and recurrent disease often points to an uncorrected host or local driver.
- Removable plaque
- Erythema
- Angular cheilitis
- Mimics
- Driver audit
oral diagnosis
Oral patterns are visible, but a white lesion is not a diagnosis until the morphology and host fit.
Recognize common forms
Pseudomembranous disease produces removable white plaques with an erythematous surface beneath. Erythematous disease can cause red, sore mucosa without prominent plaques. Angular cheilitis affects the mouth corners.
Protect the differential
Leukoplakia, oral hairy leukoplakia, lichen planus, aphthous or viral lesions, mucositis, debris, and malignancy can resemble Candida disease. A nonremovable or atypical lesion deserves reassessment.
Use testing selectively
Typical initial disease is often clinical. Potassium hydroxide microscopy, culture, species identification, or biopsy becomes more useful with atypical, recurrent, or refractory disease.
Audit recurrence
Review ART and CD4, inhaled corticosteroid technique and rinsing, denture hygiene, xerostomia, diabetes, antibiotics, nutrition, tobacco exposure, and medication adherence.
Quick check
Lesson
Treat Odynophagia as a Compartment Shift
Painful or difficult swallowing in an immunocompromised host can indicate esophageal candidiasis even when oral plaques are absent.
- Odynophagia
- Dysphagia
- Empiric trial
- Seven-day response
- Endoscopy
esophageal diagnosis
Swallowing pain shifts the problem into a deeper compartment that demands systemic exposure.
Recognize the syndrome
Odynophagia, dysphagia, substernal discomfort, food sticking, weight loss, and reduced intake support esophageal disease. Oral candidiasis increases probability but is not required.
Use an initial therapeutic trial
A systemic fluconazole trial is reasonable before endoscopy in a typical presentation. Most responsive patients improve within about 7 days.
Escalate nonresponse
If symptoms do not improve within 7 days, perform endoscopy with histopathology, culture, and speciation to identify resistant Candida, CMV, HSV, pill injury, reflux, malignancy, or another cause.
Protect intake
Severe pain can compromise hydration, nutrition, oral ART, and antifungal delivery. Select oral suspension or IV treatment and supportive care from actual swallowing ability.
Quick check
Lesson
Match Oral Therapy to Severity and Technique
Fluconazole is preferred for initial oropharyngeal disease in HIV, while selected mild localized disease can use a local formulation that the patient can administer correctly.
- Fluconazole
- Miconazole buccal
- Clotrimazole troche
- Nystatin
- 7 to 14 days
oropharyngeal treatment
Match systemic or local therapy to severity, host, technique, and adherence.
Use preferred systemic therapy
Give fluconazole 200 mg once, then 100 to 200 mg orally daily for 7 to 14 days. Review renal function, liver risk, QT risk, pregnancy, and interactions before prescribing.
Use local alternatives selectively
Miconazole 50 mg buccal once daily, clotrimazole 10 mg troche five times daily, or nystatin suspension four times daily can fit selected mild localized disease.
Treat technique as exposure
Miconazole must adhere to the upper gum, clotrimazole must dissolve slowly, and nystatin must coat and remain against the mucosa. Schedule, dexterity, saliva, taste, and cognition affect success.
Escalate correctly
Moderate or severe disease, high immune risk, recurrence, esophageal symptoms, inability to use a local product, or local-treatment failure favors systemic therapy and renewed diagnosis.
Quick check
Lesson
Deliver Systemic Therapy for 14 to 21 Days
Esophageal candidiasis always requires systemic therapy. Fluconazole is preferred, with formulation and route matched to swallowing and stability.
- Fluconazole loading
- 100 to 200 mg
- Up to 400 mg
- 14 to 21 days
- IV to oral
esophageal treatment
Fluconazole is the preferred systemic backbone, with route and alternatives shaped by the patient.
Use preferred therapy
Give fluconazole 200 mg once, followed by 100 to 200 mg daily, with doses up to 400 mg when clinically appropriate, for 14 to 21 days. Oral or IV delivery is acceptable.
Match formulation to swallowing
Oral suspension can help when pills are painful to swallow. Use IV therapy when oral delivery is not feasible, then transition to oral therapy as intake recovers.
Use systemic alternatives deliberately
Itraconazole solution, isavuconazole, voriconazole, posaconazole, lipid amphotericin B, or an echinocandin can serve selected alternative or refractory roles. Echinocandins have higher reported relapse than fluconazole.
Complete the course
Early symptom improvement does not replace the 14-to-21-day treatment duration. Track pain, swallowing, intake, weight, adverse effects, and the planned escalation date.
Quick check
Lesson
Investigate Failure Before Choosing Salvage
Refractory disease can reflect wrong diagnosis, poor adherence, inadequate exposure, interaction, resistant species, profound immune loss, or a deeper compartment.
- Culture
- Species
- Susceptibility
- Exposure
- Alternative diagnosis
refractory disease
Nonresponse is an investigation across organism, exposure, adherence, interaction, and competing diagnosis.
Verify exposure
Confirm dose, duration, formulation, route, renal adjustment, missed doses, vomiting, absorption, and interacting inducers. For local agents, directly review technique and contact time.
Obtain organism evidence
Culture, speciation, and susceptibility testing are appropriate for recurrent or refractory disease. C. glabrata, C. krusei, and azole-selected organisms can change therapy.
Reassess the diagnosis
Endoscopy and biopsy can reveal CMV, HSV, malignancy, reflux, or pill esophagitis. A nonremovable oral lesion can represent a non-Candida disorder.
Select salvage precisely
Itraconazole solution, posaconazole, voriconazole, isavuconazole, echinocandins, or lipid amphotericin can be used in selected cases. Match drug to susceptibility, site, interactions, organ function, pregnancy, and prior exposure.
Quick check
Lesson
Place Fluconazole Inside the Whole Medication System
Fluconazole is reliably absorbed and reaches mucosal tissue, but renal clearance, CYP inhibition, QT effects, liver injury, and interacting therapies shape safe exposure.
- Bioavailability
- Renal clearance
- CYP2C9
- CYP3A4
- QT
safety pk
Useful antifungal exposure sits inside renal, hepatic, electrical, and metabolic constraints.
Use pharmacokinetics
Fluconazole has high oral bioavailability and broad tissue penetration. It is primarily renally eliminated, so maintenance dosing requires renal reassessment while the loading dose is generally preserved.
Audit interactions
Fluconazole inhibits CYP2C9, CYP2C19, and CYP3A4 to varying degrees. Review warfarin, phenytoin, sulfonylureas, statins, calcineurin inhibitors, ART, and other narrow-therapeutic-index drugs.
Protect electrical safety
Fluconazole can prolong QT. Review baseline risk, potassium and magnesium, structural heart disease, and other QT-prolonging agents.
Monitor organ and immune reactions
Hepatotoxicity, rash, severe skin reactions, gastrointestinal effects, and hypersensitivity can occur. Stop and evaluate serious hepatic, mucosal, skin, or systemic findings.
Quick check
Lesson
Prevent Recurrence Through Immune and Driver Control
Routine primary antifungal prophylaxis is not recommended. Effective ART and correction of local drivers provide more durable prevention with less resistance pressure.
- ART
- No routine prophylaxis
- Driver correction
- Suppression
- Resistance
prevention art
Durable prevention comes from immune restoration and driver correction, not universal azole exposure.
Restore immunity
Start or optimize effective ART and address adherence. Recurrent mucosal candidiasis often reflects uncontrolled HIV or persistent immune suppression.
Avoid routine primary prophylaxis
Mucosal disease is usually treatable, while chronic azole exposure adds interactions, toxicity, cost, and selection pressure. Universal prophylaxis is not recommended.
Correct local drivers
Improve denture hygiene, remove dentures overnight when appropriate, rinse after inhaled corticosteroids, optimize inhaler technique and glucose, address xerostomia and nutrition, and reduce avoidable antibiotic exposure.
Reserve suppression for recurrences
Frequent or severe recurrences can justify chronic fluconazole after individualized review. Reassess ongoing need, ART control, toxicity, interactions, adherence, and resistance risk regularly.
Quick check
Lesson
Use Current Population Evidence
Pregnancy, lactation, age, organ function, swallowing ability, and polypharmacy change the safest formulation and monitoring plan.
- Pregnancy
- Lactation
- Renal
- Pediatric
- Swallowing
pregnancy populations
Treatment must protect maternal control while using current trimester and product evidence.
Prefer local therapy when appropriate
Topical therapy is preferred for oral candidiasis in pregnancy when disease severity and compartment permit. Local treatment still requires product-specific allergy and administration review.
Protect early pregnancy
Avoid oral fluconazole for vulvovaginal candidiasis in the first trimester. For invasive or refractory esophageal disease in the first trimester, current NIH guidance recommends substituting amphotericin B for fluconazole.
Use specialists for complex disease
Maternal-fetal medicine, infectious-disease, HIV, and pharmacy expertise should align maternal control, fetal risk, interactions, and treatment urgency.
Adapt route and monitoring
Renal impairment changes fluconazole exposure. Severe odynophagia can require suspension or IV therapy. Pediatric, geriatric, hepatic, and lactation contexts require current product evidence and individualized monitoring.
Quick check
Lesson
Close Every Diagnostic and Treatment Loop
Complete mucosal Candida care links tissue compartment, immune host, organism probability, formulation, route, interactions, response, escalation, and recurrence prevention.
- Compartment
- Host
- Exposure
- Response
- Ownership
integrated case
Close every loop from compartment recognition to response, escalation, and recurrence prevention.
Define the syndrome
Document oral morphology, swallowing symptoms, hydration, nutrition, immune status, local drivers, systemic danger, and alternative diagnoses.
Deliver the regimen
Record drug, formulation, loading dose, daily dose, route, renal plan, administration technique, duration, access, and interactions. Verify the patient can actually use it.
Measure response
Set a follow-up date and objective expectations for lesions, pain, swallowing, intake, weight, adherence, adverse effects, and HIV control. Esophageal nonresponse by 7 days triggers endoscopy.
Prevent recurrence
Correct devices and inhaler technique, optimize glucose and nutrition, review antibiotics, restore immune control with ART, and reserve suppression for recurrent disease with regular reassessment.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.